8.35
-0.06 (-0.71%)
| Previous Close | 8.41 |
| Open | 8.37 |
| Volume | 1,022,053 |
| Avg. Volume (3M) | 2,147,479 |
| Market Cap | 1,447,241,984 |
| Price / Sales | 151.28 |
| Price / Book | 2.12 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -1,105.21% |
| Diluted EPS (TTM) | -2.20 |
| Quarterly Revenue Growth (YOY) | -23.30% |
| Total Debt/Equity (MRQ) | 6.54% |
| Current Ratio (MRQ) | 19.96 |
| Operating Cash Flow (TTM) | -271.99 M |
| Levered Free Cash Flow (TTM) | -155.22 M |
| Return on Assets (TTM) | -28.82% |
| Return on Equity (TTM) | -45.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Relay Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -1.38 |
|
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.48% |
| % Held by Institutions | 105.68% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nextech Invest Ltd. | 31 Dec 2024 | 3,846,409 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 14.00 (Oppenheimer, 67.67%) | Buy |
| Median | 13.50 (61.68%) | |
| Low | 13.00 (Wells Fargo, 55.69%) | Buy |
| Average | 13.50 (61.68%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 7.73 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 26 Jan 2026 | 14.00 (67.66%) | Buy | 7.43 |
| Wells Fargo | 12 Dec 2025 | 13.00 (55.69%) | Buy | 8.03 |
| 07 Nov 2025 | 6.00 (-28.14%) | Hold | 6.05 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Dec 2025 | Announcement | Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 |
| 06 Nov 2025 | Announcement | Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates |
| 03 Nov 2025 | Announcement | Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November |
| 30 Oct 2025 | Announcement | Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |